Sugi Predict

Sugi Predict / Compounds / SCHEMBL9502145

SCHEMBL9502145

SCHEMBL9502145

Cc1nc2cccc(Cl)c2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 5/20 0.59
▸ TYMS P04818 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.43
▸ TNKS2 Q9H2K2 1/20 0.43
▸ ACP1 P24666 1/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ AHR P35869 1/20 0.39
▸ CLK1 P49759 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ DYRK2 Q92630 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ DYRK1B Q9Y463 1/20 0.39
▸ PBRM1 Q86U86 1/20 0.38
▸ AR P10275 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ PSMB8 P28062 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353892 0.79 PARP1 (0.56) PARP1ALDH1A1TNKS2AHRAR
SCHEMBL66296 0.79 NOS1 (0.44) PARP1TYMSALDH1A1ACP1NOS1
SCHEMBL31033488 0.79 PARP1 (0.56) PARP1ALDH1A1TNKS2AHRAR
SCHEMBL4172152 0.78 PARP1 (0.53) PARP1TYMSTNKS2CA12CA9
Bromide SCHEMBL5318093 0.78 PARP1 (0.55) PARP1ALDH1A1TNKS2AHRAR
SCHEMBL24113220 0.76 MEN1 (0.41) PARP1ALDH1A1NOS1CA12CA9
SCHEMBL5142221 0.76 PARP1 (0.59) PARP1TYMSALDH1A1TNKS2CA12
SCHEMBL3421751 0.76 ALDH1A1 (0.47) PARP1TYMSALDH1A1TNKS2ACP1
SCHEMBL1013611 0.76 PARP1 (0.46) PARP1ALDH1A1TNKS2SMN1; SMN2KDM4E
SCHEMBL12020719 0.76 ALDH1A1 (0.47) PARP1TYMSALDH1A1TNKS2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 — — EP disclosed
EP-4596548-A1 NURR1 MODULATORS Ludwig-Maximilians-Universität (DE) 2025-08-06 — — EP disclosed
WO-2024019541-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 일동제약(주) 2024-01-25 — — WO disclosed
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 — — EP disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 — — WO disclosed
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 — — US disclosed
WO-2021255086-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2021-12-23 — — WO disclosed
US-11040966-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2021-06-22 — — US disclosed
WO-2021076448-A1 SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS Crinetics Pharmaceuticals, Inc. (US) 2021-04-22 — — WO disclosed
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-11 — — US disclosed
WO-2019157458-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2019-08-15 — — WO disclosed
US-10329287-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2019-06-25 — — US disclosed
US-20170305897-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2017-10-26 — — US disclosed
US-9732075-B2 Benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2017-08-15 — — US disclosed
US-20150166527-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-06-18 — — US disclosed
CN-103040815-B Application of 2,4,6-triisopropylbenzene compounds in preparation of medicines for treating diabetes SHANGHAI INST MATERIA MEDICA 2014-12-10 — — CN disclosed
WO-2008075109-A1 SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2008-06-26 — — WO disclosed
EP-0186190-B1 BENZIMIDAZOLE DERIVATIVES, AND THEIR PRODUCTION AND USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-05-26 — — EP disclosed
US-4663339-A Acaricidal and insecticidal substituted 1-phenylalkylbenzimidazoles SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-05-05 — — US disclosed
EP-0186190-A2 Benzimidazole derivatives, and their production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1986-07-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396505-B2 Inhibitors of CaMKK2 and uses of same CAMKK2, CAMKK1, CAMK1 PARP1 1431/4885TYMS 2078/4885ALDH1A1 4136/4885
US-20150166527-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES HCRTR1, HCRTR2, NPY1R PARP1 1463/4885TYMS 3869/4885ALDH1A1 519/4885
US-10329287-B2 Benzimidazole-proline derivatives HCRTR1, HCRTR2, NPY1R PARP1 1475/4885TYMS 3884/4885ALDH1A1 604/4885
US-11040966-B2 Benzimidazole-proline derivatives HCRTR1, HCRTR2, NPY1R PARP1 1475/4885TYMS 3884/4885ALDH1A1 604/4885
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 PARP1 4610/4885TYMS 3473/4885ALDH1A1 4626/4885
US-20170305897-A1 BENZIMIDAZOLE-PROLINE DERIVATIVES HCRTR1, HCRTR2, NPY1R PARP1 1475/4885TYMS 3884/4885ALDH1A1 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.